[go: up one dir, main page]

AU2001259758A1 - Interleukin-1 inhibitors in the treatment of diseases - Google Patents

Interleukin-1 inhibitors in the treatment of diseases

Info

Publication number
AU2001259758A1
AU2001259758A1 AU2001259758A AU5975801A AU2001259758A1 AU 2001259758 A1 AU2001259758 A1 AU 2001259758A1 AU 2001259758 A AU2001259758 A AU 2001259758A AU 5975801 A AU5975801 A AU 5975801A AU 2001259758 A1 AU2001259758 A1 AU 2001259758A1
Authority
AU
Australia
Prior art keywords
interleukin
inhibitors
diseases
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001259758A
Inventor
Timothy Connor
F. Ann Hayes
Larry F. O'neal
John E. Sims
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of AU2001259758A1 publication Critical patent/AU2001259758A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
AU2001259758A 2000-05-12 2001-05-11 Interleukin-1 inhibitors in the treatment of diseases Abandoned AU2001259758A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US20388100P 2000-05-12 2000-05-12
US60/203,881 2000-05-12
US22242200P 2000-08-01 2000-08-01
US60/222,422 2000-08-01
PCT/US2001/015423 WO2001087328A2 (en) 2000-05-12 2001-05-11 Interleukin-1 inhibitors in the treatment of diseases

Publications (1)

Publication Number Publication Date
AU2001259758A1 true AU2001259758A1 (en) 2001-11-26

Family

ID=26898999

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001259758A Abandoned AU2001259758A1 (en) 2000-05-12 2001-05-11 Interleukin-1 inhibitors in the treatment of diseases

Country Status (4)

Country Link
US (3) US20010053764A1 (en)
EP (4) EP1712239A3 (en)
AU (1) AU2001259758A1 (en)
WO (1) WO2001087328A2 (en)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
US7115557B2 (en) * 1998-09-25 2006-10-03 Sciaticon Ab Use of certain drugs for treating nerve root injury
US7906481B2 (en) 1998-09-25 2011-03-15 Sciaticon Ab Specific TNF-A inhibitors for treating spinal disorders mediated by nucleous pulposus
SE9803710L (en) 1998-09-25 2000-03-26 A & Science Invest Ab Use of certain substances for the treatment of nerve root damage
US7811990B2 (en) * 1998-09-25 2010-10-12 Sciaticon Ab Soluble cytokine receptors TNF-α blocking antibodies for treating spinal disorders mediated by nucleus pulposus
EP1129190B2 (en) 1998-11-13 2017-01-11 Immunex Corporation Human tslp dna and polypeptides
WO2003032898A2 (en) 2001-07-23 2003-04-24 Immunex Corporation Modified human thymic stromal lymphopoietin
AU2002324625B2 (en) * 2001-08-07 2008-05-08 Immunex Corporation Interleukin-1 receptors in the treatment of diseases
EP1471931A4 (en) * 2001-08-24 2006-06-14 Maine Medical Ct Res Inst COPPER-DEPENDENT, NON-TRADITIONAL PROINFLAMMATORY CYTOKINE EXPORT AND METHODS, COMPOSITIONS AND KITS THAT CONCERN THESE
WO2003057162A2 (en) * 2002-01-04 2003-07-17 Combinatorx, Incorporated Combination for the treatment of immunoinflammatory disorders and proliferative skin diseases
US7572770B2 (en) * 2002-06-27 2009-08-11 University Of Zurich Use of an interleukin 1 receptor antagonist and/or pyrrolidinedithiocarbamate for the treatment or prophylaxis of type 2 diabetes
US20040214753A1 (en) * 2003-03-20 2004-10-28 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
US20050004098A1 (en) * 2003-03-20 2005-01-06 Britten Nancy Jean Dispersible formulation of an anti-inflammatory agent
DK1608407T3 (en) * 2003-03-20 2006-12-04 Pharmacia Corp Dispersible formulation of an anti-inflammatory agent
US20050009931A1 (en) * 2003-03-20 2005-01-13 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
US20040224893A1 (en) * 2003-05-06 2004-11-11 Li-Hsien Wang Methods of using IL-1 antagonists to treat neointimal hyperplasia
US20050171015A1 (en) * 2003-10-31 2005-08-04 Crabtree Gerald R. Methods and agents for enhancing bone formation or preventing bone loss
JP4989456B2 (en) * 2004-02-26 2012-08-01 ベイラー リサーチ インスティテュート Compositions and methods for systemic treatment of arthritis
US7563804B1 (en) * 2004-04-19 2009-07-21 Hovanes John Ter-Zakarian FMF treatment
EP1750746A1 (en) * 2004-06-04 2007-02-14 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat autoinflammatory disease
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
KR20070085227A (en) * 2004-08-09 2007-08-27 앨리오스 바이오파마 인크. Synthetic hyperglycosylation, protease resistant polypeptide variants, oral preparations and methods using the same
CA2577631A1 (en) * 2004-08-20 2006-03-02 Amgen Inc. Methods and compositions for treating allergic inflammation
US20060104945A1 (en) * 2004-10-05 2006-05-18 Choi Yong S Enhancement of B cell proliferation by IL-15
RU2007117716A (en) * 2004-10-12 2008-11-20 Ампротеин Корпорейшн (Us) CHIMERIC PROTEIN
WO2006076673A2 (en) * 2005-01-14 2006-07-20 Regeneron Pharmaceuticals, Inc. Use of il-i antagonists to treat polymyalgia rheumatica and giant cell arteritis
US8088773B2 (en) * 2005-05-12 2012-01-03 The Texas A&M University System Therapeutic compositions and methods
EP1881837A2 (en) * 2005-05-16 2008-01-30 The Children's Medical Center Corporation Method of treating lymphangioleiomyomatosis (lam)
ES2335232T3 (en) * 2005-06-21 2010-03-23 Xoma Technology Ltd. ANTIBODIES AND FRAGMENTS OF THE SAME THAT JOIN THE IL-1 BETA.
US20070248597A1 (en) * 2005-10-21 2007-10-25 Henley Charles M Iii Methods of decreasing vascular calcification using IL-1 inhibitors
JP2009513645A (en) 2005-10-26 2009-04-02 ノバルティス アクチエンゲゼルシャフト Novel use of IL-1β compounds
CA2673592C (en) * 2006-12-20 2014-03-25 Xoma Technology Ltd. Methods for the treatment of il-1.beta. related diseases
US8034014B2 (en) 2007-03-06 2011-10-11 Biomet Biologics, Llc Angiogenesis initation and growth
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
JP2010528086A (en) * 2007-05-29 2010-08-19 ノバルティス アーゲー New indications for anti-IL-1 therapy
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
WO2009033732A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of the peptide phpfhlfvy (renin inhibitor) as a therapeutic agent
WO2009033664A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of delta-endorphin as a therapeutic agent
AU2008306141A1 (en) * 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Thyrotropin releasing hormone for therapeutic applications
EP2391650B1 (en) * 2007-12-20 2014-10-15 Xoma (Us) Llc Methods for the treatment of gout
US20090191287A1 (en) * 2008-01-29 2009-07-30 Johnson W Dudley Mitigation of Inflammation-Related Injuries
EP2620139B1 (en) 2008-02-27 2016-07-20 Biomet Biologics, LLC Interleukin-1 receptor antagonist rich solutions
US8753690B2 (en) 2008-02-27 2014-06-17 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
JP5607613B2 (en) * 2008-06-06 2014-10-15 ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー Methods for the treatment of rheumatoid arthritis
US20100069343A1 (en) * 2008-07-18 2010-03-18 Andrea Vambutus Methods of predicting steroid responsiveness with Il-1RII
WO2010028275A1 (en) 2008-09-05 2010-03-11 Xoma Technology Ltd. METHODS FOR TREATING OR PREVENTING IL-1ß RELATED DISEASES
US8389474B1 (en) * 2009-07-14 2013-03-05 Alan Anson Wanderer Rationale for IL-1 β targeted therapy to improve harvested organ viability, allograft tolerance, replant success and for conditions characterized by reduced or absent arterial perfusion
US20110052561A1 (en) * 2009-08-27 2011-03-03 Biomet Biologics,LLC Osteolysis treatment
WO2011031553A2 (en) 2009-08-27 2011-03-17 Biomet Biologics, Llc Implantable device for production of interleukin-1 receptor antagonist
WO2011029870A1 (en) * 2009-09-10 2011-03-17 Cytos Biotechnology Ag Use of interleukin-1 beta mutein conjugates in the treatment of diabetes
CN101690801B (en) * 2009-10-26 2012-08-01 上海交通大学 Application of interleukin-1 receptor antagonist and medicinal composition thereof
KR20130086141A (en) * 2010-04-16 2013-07-31 메디뮨 리미티드 Compositions and methods for treating copd exacerbation
PH12012502143A1 (en) 2010-05-07 2019-07-03 Xoma Us Llc Methods for the treatment of il-1beta related conditions
EP2598526B1 (en) 2010-07-29 2018-09-05 Eleven Biotherapeutics, Inc. Chimeric il-1 receptor type i agonists and antagonists
JP2013536841A (en) 2010-09-03 2013-09-26 バイオメット、バイオロジクス、リミテッド、ライアビリティー、カンパニー Methods and compositions for delivering interleukin-1 receptor antagonists
JP6450364B2 (en) 2013-03-13 2019-01-09 セセン バイオ， インコーポレイテッド Chimeric cytokine formulations for ocular delivery
US10143725B2 (en) 2013-03-15 2018-12-04 Biomet Biologics, Llc Treatment of pain using protein solutions
US9758806B2 (en) 2013-03-15 2017-09-12 Biomet Biologics, Llc Acellular compositions for treating inflammatory disorders
US9895418B2 (en) 2013-03-15 2018-02-20 Biomet Biologics, Llc Treatment of peripheral vascular disease using protein solutions
US20140271589A1 (en) 2013-03-15 2014-09-18 Biomet Biologics, Llc Treatment of collagen defects using protein solutions
US9950035B2 (en) 2013-03-15 2018-04-24 Biomet Biologics, Llc Methods and non-immunogenic compositions for treating inflammatory disorders
US9878011B2 (en) 2013-03-15 2018-01-30 Biomet Biologics, Llc Treatment of inflammatory respiratory disease using biological solutions
US10208095B2 (en) 2013-03-15 2019-02-19 Biomet Manufacturing, Llc Methods for making cytokine compositions from tissues using non-centrifugal methods
US9833474B2 (en) 2013-11-26 2017-12-05 Biomet Biologies, LLC Methods of mediating macrophage phenotypes
GB201412410D0 (en) * 2014-07-11 2014-08-27 Isis Innovation Treatment
US10441635B2 (en) 2014-11-10 2019-10-15 Biomet Biologics, Llc Methods of treating pain using protein solutions
US9763800B2 (en) 2015-03-18 2017-09-19 Biomet C. V. Implant configured for hammertoe and small bone fixation
WO2020245464A1 (en) * 2019-06-07 2020-12-10 Linnane Pharma Ab Treatment and diagnosis of chronic inflammatory conditions in the lower urinary tract
EP4168034B1 (en) * 2020-06-22 2025-11-26 Imunami Laboratories Pte. Ltd. Recombinant alpha-a-crystallin and combinations for use in the treatment of cancer
US20260015427A1 (en) 2024-06-25 2026-01-15 Kiniksa Pharmaceuticals, Gmbh Formulations of anti-interleukin 1 receptor 1 antibodies

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6008217A (en) 1995-12-20 1999-12-28 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US6204261B1 (en) 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US5874424A (en) 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US5196430A (en) 1986-12-31 1993-03-23 Hoechst-Roussel Pharmaceuticals Inc. Method of inhibiting the activity of leukocyte derived cytokines
US5096906A (en) 1986-12-31 1992-03-17 University Of Virginia Alumni Patents Foundation Method of inhibiting the activity of leukocyte derived cytokines
US5081228A (en) 1988-02-25 1992-01-14 Immunex Corporation Interleukin-1 receptors
US5319071A (en) 1987-11-25 1994-06-07 Immunex Corporation Soluble interleukin-1 receptors
WO1989004838A1 (en) * 1987-11-25 1989-06-01 Immunex Corporation Interleukin-1 receptors
USRE35450E (en) 1987-11-25 1997-02-11 Immunex Corporation Soluble human interleukin-1 receptors, compositions and method of use
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5296592A (en) * 1987-11-25 1994-03-22 Immunex Corporation Process for purifying interleukin-1 receptors
DE3817955A1 (en) 1988-05-27 1989-11-30 Hoechst Ag MEDICINAL PRODUCT CONTAINING TNF INHIBITOR
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
GB9413975D0 (en) 1994-07-11 1994-08-31 Fujisawa Pharmaceutical Co New heterobicyclic derivatives
US5064837A (en) * 1989-11-13 1991-11-12 Schering Corporation 3-substituted-1-aryl-2(h)-quinolones and their pharmaceutical compositions
AU649245B2 (en) * 1990-04-02 1994-05-19 Amgen, Inc. Methods for treating interleukin-1 mediated diseases
WO1991015577A1 (en) 1990-04-04 1991-10-17 Black, Roy, A. INTERLEUKIN 1'beta' PROTEASE
US5162361A (en) * 1990-04-10 1992-11-10 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Method of treating diseases associated with elevated levels of interleukin 1
WO1991017184A1 (en) 1990-04-27 1991-11-14 The Upjohn Company Modified interleukin-1 inhibitors
US5872095A (en) * 1990-05-01 1999-02-16 Chiron Corporation IL-1 receptor antagonists medicaments
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
DE59109269D1 (en) 1990-06-28 2005-12-15 Hoechst Ag Fusion proteins with immunoglobulin components, their preparation and use
DE69122084T2 (en) * 1990-11-30 1997-04-03 Teijin Ltd., Osaka 2-ARYLTHIAZOLE DERIVATIVE AND THIS MEDICINAL PRODUCT
AU9106491A (en) * 1991-01-17 1992-08-27 Upjohn Company, The Method of preventing and treating insulin dependent diabetes mellitus
DE69233069T2 (en) 1991-03-15 2003-11-27 Amgen Inc., Thousand Oaks PEGYLATION OF POLYPEPTIDES
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
AU657701B2 (en) 1991-08-30 1995-03-23 Vertex Pharmaceuticals Incorporated Interleukin 1beta protease and interleukin 1beta protease inhibitors
AU674292B2 (en) * 1991-10-15 1996-12-19 Immunex Corporation Methods and compositions for treating allergic reactions
GB9123326D0 (en) 1991-11-04 1991-12-18 Sandoz Ltd Improvements in or relating to organic compounds
EP0547699A1 (en) 1991-12-19 1993-06-23 Merck & Co. Inc. Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme
WO1993014777A1 (en) 1992-01-31 1993-08-05 Merck & Co., Inc. PEPTIDYL DERIVATIVES AS INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME
DE69320176T2 (en) 1992-02-21 1999-04-08 Merck & Co., Inc., Rahway, N.J. PEPTIDYL DERIVATIVES AND INHIBITORS OF THE INTERLEUKIN-1-G (B)-CONVERTING ENZYME
US5547979A (en) 1992-03-30 1996-08-20 Smithkline Beecham TNF inhibition
JPH07509223A (en) * 1992-04-30 1995-10-12 アムジェン インコーポレイテッド Methods for treating interleukin-1-mediated and tumor necrosis factor-mediated diseases
GB9223904D0 (en) 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
US5521315A (en) * 1993-01-12 1996-05-28 Cell Therapeutics, Inc. Olefin substituted long chain compounds
EP0628550B1 (en) 1993-06-08 1998-02-25 Sanofi Pyridazines as interleukin-1beta converting enzyme inhibitors
GB9320660D0 (en) 1993-10-07 1993-11-24 British Bio Technology Inhibition of cytokine production
US5508300A (en) 1994-01-14 1996-04-16 Pfizer Inc. Dihydro pyrazolopyrroles, compositions and use
DE69502378T2 (en) 1994-01-20 1998-10-01 British Biotech Pharm METALOPROTEINAS INHIBITORS
WO1995026958A1 (en) 1994-03-31 1995-10-12 Sanofi Winthrop, Inc. Pyrimidinyl derivatives as interleukin inhibitors
US5519000A (en) 1994-04-01 1996-05-21 Centecor, Inc. Tumor necrosis factor inhibitors
US5552400A (en) 1994-06-08 1996-09-03 Sterling Winthrop Inc. Fused-bicyclic lactams as interleukin-1β converting enzyme inhibitors
US5716929A (en) 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5847135A (en) 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
US5756466A (en) 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
GB9412672D0 (en) 1994-06-23 1994-08-10 Celltech Ltd Chemical compounds
AU698393B2 (en) * 1994-06-24 1998-10-29 Immunex Corporation Controlled release polypeptide compositions and methods of treating inflammatory bowel disease
GB2291422A (en) 1994-07-18 1996-01-24 Fujisawa Pharmaceutical Co 4-phenyl-pyrido[2,3-b]pyrazin-4-ones
IT1269989B (en) 1994-09-21 1997-04-16 Dompe Spa IL-1 RECEPTOR ANTAGONISTS WITH INCREASED INHIBITORY ACTIVITY
US5563143A (en) 1994-09-21 1996-10-08 Pfizer Inc. Catechol diether compounds as inhibitors of TNF release
US5656624A (en) * 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
US5861510A (en) 1995-04-20 1999-01-19 Pfizer Inc Arylsulfonyl hydroxamic acid derivatives as MMP and TNF inhibitors
US5641751A (en) 1995-05-01 1997-06-24 Centocor, Inc. Tumor necrosis factor inhibitors
US5753628A (en) 1995-06-07 1998-05-19 Centocor, Inc. Peptide inhibitors of TNF containing predominantly D-amino acids
US5843904A (en) 1995-12-20 1998-12-01 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1βconverting enzyme
ES2334726T3 (en) * 1996-02-09 2010-03-15 Amgen Inc. COMPOSITION THAT INCLUDES IL-1RA AS AN INHIBITOR OF INTERLEUCINE 1 AND HIALURONANE AS A CONTROLLED LIBERATION POLYMER.
US5776731A (en) * 1996-02-21 1998-07-07 Immunex Corporation DNA encoding type-I interleukin-I receptor-like protein designated 2F1
JP2000506526A (en) * 1996-03-15 2000-05-30 ザ・ジェネラル・ホスピタル・コーポレイション Programmed cell death and interleukin-1β
CA2223006A1 (en) * 1996-04-03 1997-10-09 Kyowa Hakko Kogyo Co., Ltd. Physiologically active substance ei-2128-1
GB9607120D0 (en) 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
WO1997044322A1 (en) 1996-05-20 1997-11-27 Darwin Discovery Limited Quinoline sulfonamides as tnf inhibitors and as pde-iv inhibitors
EP0818439B1 (en) * 1996-07-02 1999-10-13 Nisshin Flour Milling Co., Ltd. Imide derivatives
US6054559A (en) * 1997-01-28 2000-04-25 Smithkline Beecham Corporation Interleukin-1 receptor antagonist beta (IL-1raβ)
US5883131A (en) 1997-07-09 1999-03-16 Pfizer Inc. Cyclic sulfone derivatives
WO1999004001A1 (en) 1997-07-21 1999-01-28 Zymogenetics, Inc. Tumor necrosis factor receptor ztnfr-5
WO1999015524A1 (en) 1997-09-23 1999-04-01 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivatives
US6020339A (en) 1997-10-03 2000-02-01 Merck & Co., Inc. Aryl furan derivatives as PDE IV inhibitors
US6080580A (en) 1998-10-05 2000-06-27 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of tumor necrosis factor-α (TNF-α) expression
US6306978B1 (en) * 1999-02-05 2001-10-23 General Electric Company Capping of polyphenylene ether resin
US6086095A (en) 1999-07-30 2000-07-11 Milliken & Company Airbag cushion exhibiting low seam and fabric usage and simultaneously high available inflation volume
US7572770B2 (en) * 2002-06-27 2009-08-11 University Of Zurich Use of an interleukin 1 receptor antagonist and/or pyrrolidinedithiocarbamate for the treatment or prophylaxis of type 2 diabetes

Also Published As

Publication number Publication date
EP2329842A2 (en) 2011-06-08
WO2001087328A3 (en) 2002-08-22
EP1712239A2 (en) 2006-10-18
EP2329842A3 (en) 2011-07-27
EP1712239A3 (en) 2007-08-22
US20010053764A1 (en) 2001-12-20
WO2001087328A2 (en) 2001-11-22
US20040023869A1 (en) 2004-02-05
EP1282435A2 (en) 2003-02-12
US20090022733A1 (en) 2009-01-22
EP2241328A1 (en) 2010-10-20

Similar Documents

Publication Publication Date Title
AU2001259758A1 (en) Interleukin-1 inhibitors in the treatment of diseases
PL374118A1 (en) Interleukin-1 receptors in the treatment of diseases
AU2000260550A1 (en) Treatment of skin damage using polyenylphosphatidylcholine
IL155092A0 (en) Compounds useful in the treatment of inflammatory diseases
AU2002248269A1 (en) Use of p38 inhibitors for the treatment of inflammation-enhanced cough
AU2002225954A1 (en) Dipeptidylpeptidases and methods of use
AU2002247208A1 (en) Selective pde3b inhibitors and use of the same in therapy
AU2001245987A1 (en) Compositions and methods for gene therapy
AU2002210385A1 (en) Furazanyl-triazole derivates for the treatment of diseases
AU2002233928A1 (en) Cycloalkylfused (g)-indole compounds as spla2-inhibitors in the treatment of inflammatory diseases
AU2002241661A1 (en) Multifunctional protease inhibitors and their use in treatment of disease
AUPR074500A0 (en) Treatment of t cell disorders
AU2001260834A1 (en) The treatment of herpes
AU2001236713A1 (en) Methods for treatment of lysosomal storage diseases
AU2001265186A1 (en) Use of epoxyeicosatrienoic acids in the treatment of cerebrovascular conditions
IL155174A0 (en) Methods and compositions for the treatment of inflammatory diseases
AU2003206945A1 (en) Use of proteinase inhibitors in the treatment of autoimmune diseases
AU2001292818A1 (en) Use of transcription factors for treating inflammation and other diseases
AU2003244455A1 (en) Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases
AU2002210763A1 (en) Use of 1-ebio in the treatment of bipolar disorders
AU2001255168A1 (en) Compositions and methods for the treatment of immune related diseases
AU2003240446A1 (en) Use of mob-5 in pain
AU2001253560A1 (en) Methods of treatment
AU2001262520A1 (en) Combined preparation for the treatment of neoplasic diseases
AU2001275165A1 (en) Treatment of side effects associated with alcohol consumption